Clinical prognostication and immunotherapy response prediction in esophageal squamous cell carcinoma using the <scp>DNA</scp> damage <scp>repair‐associated</scp> signature

Abstract

Through the integration of single-cell and bulk RNA-seq data, we have developed a DAS associated with prognosis and immunotherapy response. This signature holds promise for the future stratification and personalized treatment of ESCC patients in clinical settings.